Barrett Alan D T
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0436, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555-0436, USA.
Vaccine. 2017 Oct 20;35(44):5951-5955. doi: 10.1016/j.vaccine.2017.03.032. Epub 2017 Mar 30.
Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.
黄热病被视为最初的出血热,至少250年来一直是一个重大的公共卫生问题。20世纪30年代研制出了一种非常有效的减毒活疫苗——17D株,事实证明,这种疫苗对控制该疾病至关重要。毫无疑问,如果没有这种疫苗,黄热病毒将被视为生物安全4级病原体。值得注意的是,黄热病是目前《国际卫生条例》规定需要国际疫苗接种证书的唯一疾病。尽管有非常成功的疫苗,但偶尔也会出现供需问题,比如2016年安哥拉和刚果民主共和国出现的疫苗供应不足的情况。首次在紧急情况下批准了疫苗的分剂量接种。因此,未来需要持续保持警惕并改善供需情况。